Bit.bio is an award-winning spinout from the University of Cambridge that combines synthetic and stem cell biology for the precise, efficient, and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. As a team of individuals, they value science, collaboration, openness, curiosity and creativity, united by trust and respect for each other.
Owning global responsibility for assigned strategic accounts, driving expansion of bit.bio’s footprint and share of customer wallet across all relevant sites.
Developing, implementing and executing global Senior Strategic Account strategies that convert accounts from tactical to strategic partnerships.
Driving revenue growth for the ioCells business while identifying additional revenue opportunities across the broader portfolio, including CRISPR screens, custom derivatives and new cell type development.